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ABSTRACT 
BACKGROUND:  The drug 3,4-methylenedioxymethamphetamine (MDMA), other- 
wise known as "ecstasy," is a synthetic amphetamine that produces euphoria, increases 
sociability and energy, and is often used as a "weekend" recreational drug by young 
adults. 
CASE SUMMARY:  A 23-year-old male (height, 184 cm; weight, 68 kg) pre- 
sented to the emergency department of Marmara University Hospital, Istanbul, 
Turkey, with jaundice and nausea lasting for 6 days. The patient reported that he had 
been a chronic user of MDMA for 2 years. He also reported that 1 week before present- 
ing, he had ingested twice (2 tablets) the usual amount (1 tablet) of the drug at the 
same time. Blood tests were performed and hematologic findings were as follows: 
aspartate aminotransferase (AST), 1423 U/L (reference range, 10-37 U/L); alanine 
aminotransferase (ALT), 2748 U/L (10-40 U/L); alkaline phosphatase, 271 U/L 
(0-270 U/L); 7-glutamyl transpeptidase, 124 U/L (7-49 U/L); total bilirubin, 
13.23 mg/dL (0.2-1 mg/dL); direct bilirubin, 8.75 mg/dL (0-0.3 mg/dL); amylase, 
80 U/L (0-220 U/L); prothrombin time, 21.2 sec; activated partial thromboplastin 
time, 37.3 sec; and international normalized ratio, 1.66. Liver enzymes and bilirubin 
levels were found to be extremely high (AST = 40x normal, ALT = 70× normal, and 
bilirubin = 13x normal). Viral, autoimmune, and metabolic auses were excluded. 
Serologic tests for hepatitis A, B, and C viruses, mononucleosis, cytomegalovirus, and 
HIV infection were all negative. A diagnosis of ecstasy-induced toxic hepatitis was 
made. The patient's medical history further revealed that the current incident was 
actually his second occurrence of jaundice and acute hepatitis associated with the 
ingestion of higher amounts (twice the usual amount of MDMA he ingested at the 
same time). Supportive therapy (IV saline and vital sign monitoring) was initiated and 
liver enzymes, bilirubin levels, and prothrombin times were monitored aily. All had 
returned to normal values in 2 weeks. 
CONCLUSIONS:  MDMA, or the recreational drug ecstasy, might be responsible 
for acute hepatitis and/or acute liver failure, particularly in young people. Physicians 
might need to be alert to the possibility of ecstasy-induced liver damage occurring in 
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younger patients, although the presence of other hepatotoxins and alternative diagno- 
ses requires exclusion. The use of this drug should be investigated in young patients 
with severe hepatitis of unknown origin. (Curr Ther Res Clin Exp. 2008;69:260-265) 
© 2008 Excerpta Medica Inc. 
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INTRODUCTION 
The drug 3,4-methylenedioxymethamphetamine (MDMA), otherwise known as 
ecstasy, isa synthetic ompound with structural and pharmacologic similarities to both 
amphetamines and mescaline. 1 Because it elicits feelings of euphoria, wakefulness, 
intimacy, sexual arousal, and disinhibition, MDMA has become a common drug of 
abuse, particularly among young adult party-goers. 2 For the purposes of this article, 
the terms "MDMA" and "ecstasy" will be used interchangeably. 
MDMA is a sympathomimetic drug that causes release of endogenous cate- 
cholamines (particularly norepinephrine and dopamine) and blocks their reuptake 
into presynaptic vesicles. 3The concentrations of MDMA contained in illicitly pro- 
duced pills vary widely. 3The typical dosage range for recreational use varies from 50 
to 200 mg, but the actual amount per tablet in different batches of tablets might vary 
70-fold or more: from almost 0 to well over 100 mg. 1,3,4 An examination of tablets 
sold as ecstasy in Europe between 1995 and 1997 revealed that of 69 tablets with an 
identifying logo, 30 contained MDMA, with doses ranging from 2 to 149 mg, and 
another 8 contained a mixture of substances including amphetamines, ephedrine, caf- 
feine, and aspirin. Overall, -10% of drugs sold as ecstasy contain no active ingredient. 5 
MDMA is typically ingested orally as a tablet and is readily absorbed in the gas- 
trointestinal tract. Peak effects occur within 2 hours of ingestion and typically last 
4 to 6 hours. Up to 75% of MDMA is excreted in the urine unchanged, while the 
remainder is primarily metabolized in the liver by the cytochrome P450 P2D6 
(CYP2D6). 6-8 Major toxicity and death could occur after ingestion of a single tablet; 
ingestion of larger quantities carries greater isk for toxicity. 9Erroneously believed to 
be a "safer" drug of abuse compared with amphetamine, MDMA actually shares the 
toxicity of amphetamine and possesses unique toxicities, both acute and chronic. 9
MDMA has also been associated with fulminant hepatic failure and should be consid- 
ered in the differential diagnosis of hepatic failure in young people. 9
We present ayoung patient, a chronic ecstasy user, who ingested twice his amount 
of ecstasy (ie, MDMA; 2 tablets at the same time) and developed jaundice and ecstasy- 
induced toxic hepatitis. 
CASE SUMMARY 
A 23-year-old male (height, 184 cm; weight, 68 kg) presented to the emergency 
department of Marmara University Hospital, Istanbul, Turkey, with jaundice, dark 
urine, and nausea lasting for 6 days. On arrival, the patient was found to be dehy- 
drated, pale, and weak. During assessment questioning, the patient reported that he 
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had been a chronic ecstasy user for 2 years and usually ingested anywhere from 2 to 
3 tablets of ecstasy each month while at parties, totaling 1 tablet per party night. The 
patient also reported that 1 week before presenting, he had ingested twice his normal 
amount of ecstasy tablets at the same time along with alcohol. His vital signs were as 
follows: blood pressure, 110/70 mm Hg; heart rate, 64 bpm; respiratory rate, 14 per 
minute; and body temperature, 36°C. Physical examination revealed no pathologic 
finding except dry and yellow skin. Blood tests were performed and results were as 
follows: total bilirubin, 13.23 mg/dL (reference range, 0.2-1 mg/dL); direct bilirubin, 
8.75 (0-0.3 mg/dL); prothrombin time, 21.2 sec; activated partial thromboplastin 
time, 37.3 sec; aspartate aminotransferase, 1423 (10-37 U/L); alanine aminotransfer- 
ase, 2748 (10-40 U/L); 7-glutamyl transpeptidase, 124 (7-49 U/L); alkaline phos- 
phatase, 271 (0-270 U/L); amylase, 80 (0-220 U/L); and international normalized 
ratio, 1.66. Viral, autoimmune, and metabolic auses were excluded. Serologic tests 
for hepatitis A, B, and C virus, mononucleosis, cytomegalovirus (CMV), and HIV 
infection were all negative. Ceruloplasmin (0.248 [range, 0.2-0.6 g/L]), iron (150 
[59-158 lag/dL]), and ferritin (227 [30-400 ng/mL]) levels were normal, and anti- 
nuclear antibodies, antimitochondrial ntibody, antismooth muscle antibody, and 
liver-kidney microsomal antibody were also negative. Abdominal ultrasound was 
unremarkable. A diagnosis of ecstasy-induced toxic hepatitis was made and the 
patient was admitted to the emergency department. The patient did not give consent 
for liver biopsy. 
On further questioning, the patient reported that he had previously experienced 
jaundice and acute hepatitis adverse vents after ingestion of a higher amount han 
his usual ecstasy tablet dosage (ie, 2 tablets vs 1 tablet). The previous occurrence was 
8 months prior to the current incident, with the same clinical status and the develop- 
ment of jaundice. The patient was admitted to Taksim State Hospital (Istanbul, 
Turkey) for 2 weeks and discharged without sequelae. Unfortunately, we could not 
obtain the records or laboratory results for this prior incident. 
The patient's liver enzymes, bilirubin levels, and prothrombin times were moni- 
tored daily and supportive therapy (IV fluid infusion and vital sign monitoring) was 
initiated during the confinement period (6 days) for this current incident. The patient 
was followed for 1 month. Liver enzymes and bilirubin levels returned to normal val- 
ues within 2 weeks (Figure). 
DISCUSSION 
Acute liver dysfunction confirmed by liver function test abnormalities might occur 
with infection caused by hepatitis viruses and other hepatotropic viruses (eg, CMV, 
herpes implex, Coxsackie, Epstein-Barr). Other causes include a variety of toxins (eg, 
acetaminophen, ethanol, mushrooms, metals, various other medications), and autoim- 
mune and metabolic hepatobiliary diseases. I° After eliminating these specific causes, 
idiosyncratic drug reactions remain as other possible causes. Hepatic injury associated 
with MDMA (ie, ecstasy) use is one of these miscellaneous less common causes. 
Several cases of hepatic injury associated with ecstasy use, with signs and symptoms 
ranging from benign forms that mimic acute viral hepatitis, to severe forms such as 
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Figure. The timeline of change after ecstasy ingestion in (A) activated partial 
thromboplastin time (aPTT), prothrombin time (PT), total bilirubin (TBIL), 
direct bilirubin, and (B) related liver function tests that included alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 
(ALP), and ~,-glutamyl transpeptidase (GGT). 
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liver failure due to massive hepatic necrosis, have been described.ll Our patient was diag- 
nosed with ecstasy-induced toxic hepatitis based on having met the following criteria: no 
positive serologic markers to support he diagnosis of viral hepatitis; other hepatic diseases 
that could produce asharp increase in serum aminotransferase levels in young people such 
as autoimmune hepatitis or Wilson's disease were ruled out; there was exposure to the drug 
before development of symptoms; there was clinical improvement when the toxic agent 
was discontinued; the patient relapsed when he was re-exposed to the drug based on the 
patient's own report; and pre-existing liver disease was excluded by clinical history and 
follow-up. Based on a score of 11 on the Naranjo adverse drug reaction probability scale, 12 
ecstasy was the "definite" cause of toxic hepatitis in this patient. 
The mechanism of ecstasy-induced toxic hepatitis has not been determined. It is 
believed to possibly be related to some metabolite of the drug or to some contami- 
nant in its preparation. 13MDMA and related drugs are largely metabolized in the 
liver by CYP2D6. The immediate product of this reaction is then processed further 
by other enzymes into a variety of secondary products, some of which are highly 
reactive with glutathione. A marked decrease in the level of free glutathione is 
related to a series of biochemical changes (eg, massive influx of calcium, oxidative 
change in the cell-membrane lipids) that result in cell death) ,8 Spontaneous recov- 
ery usually occurs over a period of a few weeks to many months, but in chronic users 
of MDMA there could be repeated attacks of hepatitis) It has been suggested that 
in any case of repeated acute hepatitis in a young person, the use of MDMA should 
be suspected as a possible cause. Andreu et a111 found that in their hospital, ecstasy 
was the second most common cause of liver injury in patients under the age of 
25 years. In their findings, 26 of the 62 patients tudied were aged <25 years, and 
in 10 of these patients, the most common mechanisms associated with acute hepa- 
titis were ruled out by clinical and serologic riteria. Further, among these 10 cases, 
50% (5/10) were ecstasy related, ll Also, genetic enzyme deficiency and immune- 
mediated mechanisms have been hypothesized. 9 Postmortem studies by Milroy et a113 
found that MDMA- and 3,4-methylenedioxy-N-ethyl-amphetamine-related fatali- 
ties were associated with hepatic, myocardial, and brain tissue damage. It has been 
suggested that MDMA-associated rhabdomyolysis and other organ damage occur as 
a consequence of hyperthermia, lthough Ellis et a114 reported 8 cases of MDMA- 
associated liver damage, 4 in which the patients had not been hyperthermic. We do 
not have any evidence that our patient was hyperthermic, but the dose dependent 
similar clinical findings suggest hat enzyme (CYP2D6) deficiency mechanism was 
more likely to be the cause of recurrent jaundice and recurrent toxic hepatitis. 
Our patient had ingested a double dose of ecstasy with alcohol; a case in which the 
potentiating effect of alcohol is unknown. The exact amount of ecstasy and the contami- 
nants are unknown as well. Further, it is not known whether toxicity is dose related) 5 
One case of fulminant hepatitis and 2 cases of acute hepatitis after ingestion of just 
1 tablet of ecstasy have been reported in the literature, ll Shearman et a116 reported a
patient who developed recurrent acute hepatitis associated with repeated ecstasy use; 
but their patient was not a chronic ecstasy user and the condition was interpreted as 
an idiosyncratic response to either ecstasy or a contaminant in the preparation. 
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CONCLUSIONS 
We report a case of recurrent toxic hepatitis in a young adult after ecstasy ingestion. 
Ecstasy might be responsible for cases of acute hepatitis and acute liver failure in 
young people. Health care providers need to be alert to the possibility of ecstasy- 
induced liver damage occurring in younger patients, although the presence of other 
hepatotoxins and alternative diagnoses require exclusion. Therefore, the use of this 
drug should be investigated in all patients with severe hepatitis of unclear origin. 
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